Avita Medical Reports Results of RECELL System in Investigational Device Exemption (IDE) Compassionate Use and Continued Access Studies for Third-Degree Burns in Pediatric Patients

 Avita Medical Reports Results of RECELL System in Investigational Device Exemption (IDE) Compassionate Use and Continued Access Studies for Third-Degree Burns in Pediatric Patients

Avita Medical Reports Results of RECELL System in Investigational Device Exemption (IDE) Compassionate Use and Continued Access Studies for Third-Degree Burns in Pediatric Patients

Shots:

  • The IDE compassionate use and continued access studies involve assessing of Spray-On Skin Cells prepared using the RECELL system + meshed autografts in 107 pediatric patients with deep burn injuries
  • The interim analyses results: healing within 4wks. (98%); patients with >50% TBSA achieve the same rate of healing as patients with ≤50% TBSA; donor sites healed within a wk. & 2wks. (62.5% & 100%); Presented at the American Burn Association (ABA)
  • The RECELL system is an autologous cell harvesting device utilizes the patient’s own skin to produce a suspension of Spray-On Skin Cells in 30mins. for the treatment of thermal burns. In Sept’18, it has received FDA’s approval for acute thermal burns in patients ≥ 18yrs. with TGA registration in Australia & CFDA clearance in China

Click here to read full press release/ article | Ref: Avita Medical | Image: MedGadget

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post